Low-dose alteplase does not provide additional benefits over standard-dose alteplase in people with lacunar acute ischemic stroke.
Why this matters
In the alteplase-dose arm of the Enhanced Control of Hypertension and Thrombolysis Stroke Study, a lower dose of intravenous alteplase was linked to reduced risk of intracerebral hemorrhage versus the standard-dose in thrombolysis-eligible acute ischemic stroke individuals. This study investigated whether this is also true for lacunar acute ischemic stroke. The findings suggest that people with lacunar acute ischemic stroke should receive standard dose intravenous alteplase as with other acute ischemic stroke subtypes.